Compugen

CGENPhase 2

Holon, Israelcgen.com

Compugen is transforming the pathway to immuno-oncology therapeutics through its unique 'From Code to Cure®' approach. Its flexible-loop Unigen™ platform integrates AI/ML innovation with biological data to discover novel targets and develop first-in-class drugs for cancer patients refractory to current treatments. The company has validated its platform through multiple partnerships with pharmaceutical companies and is advancing a pipeline of clinical-stage programs targeting novel pathways in immuno-oncology.

Market Cap

$197.6M

Focus

Biologics

CGEN · Stock Price

USD 2.091.17 (-35.89%)

Historical price data

AI Company Overview

Technology Platform

Unigen™ is an AI/ML-powered flexible-loop platform that integrates multi-omics, single-cell RNA sequencing, and spatial omics data to computationally predict novel drug targets and develop first-in-class cancer immunotherapies.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
COM701 + Normal Saline	Ovarian Cancer	Phase 1/2
Dose escalation: COM902 monotherapy. + Cohort expansion: COM902 (RDFE) monothera...	Advanced Cancer	Phase 1

Funding History

Total raised: $105M

PIPE$35MOrbiMed AdvisorsJan 15, 2018

PIPE$40MOrbiMed AdvisorsDec 15, 2013

IPO$30MUndisclosedMar 15, 2000

Opportunities

The significant unmet need in immuno-oncology (60-80% non-responders to current therapies) creates substantial market opportunity for novel mechanisms.

Compugen's computational platform enables efficient discovery of first-in-class targets, potentially creating new market segments and partnership opportunities with larger pharma companies seeking innovative pipelines.

Risk Factors

High clinical development risk for first-in-class mechanisms, dependence on platform validation, intense competition in immuno-oncology, and financial vulnerability as a clinical-stage public company dependent on equity markets for funding.

Competitive Landscape

Competes with large pharma immuno-oncology leaders (Merck, BMS, Roche) and computational discovery peers (Recursion, Exscientia). Differentiates through integrated computational discovery and internal development capabilities, focusing on novel targets rather than competing in crowded established pathways.